Topics:
Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Ohio State University
How would you approach frontline treatment of a patient with metastatic non-squamous NSCLC with ERBB2 amplification and PD-L1 > 50%?
In the absence of a frontline clinical trial, would you treat with carboplatin+pemetrexed+pembrolizumab or consider IMPOWER 150 or other?
Answer from: Medical Oncologist at Academic Institution
This interesting case brings up how to separate in our work fact from fiction. We are presented with a case of a patient with metastatic non-squamous non-small cell lung cancer with a PD-L1 TPS score of 55% and ERBB2 amplification by Foundation One testing.What is the right approach? Standard chemo/...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Regarding front line therapy for ERBB2/HER2 alterations for NSCLC in the era of immune checkpoint inhibition, limited data is available. The most extensive data presented is based on ERBB2 exon 20 insertion mutations rather than amplification in NSCLC. Mazieres and colleagues published on the ...
Answer from: Medical Oncologist at Academic Institution
Very erudite discussions by both @Karen L. Reckamp and @Balazs Halmos. I've very little to add. I just want to remind readers that this patient would have been eligible technically for either KN 024 or KN 189 since neither study explicitly excluded ERBB2/HER2 abnormalities, only EGFR and ALK. C...